| 21.6 -1.14 (-5.01%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 35.82  |
1-year : | 42.92 |
| Resists | First : | 30.67 |
Second : | 36.75 |
| Pivot price | 25.49 |
|||
| Supports | First : | 20.84 |
Second : | 17.33 |
| MAs | MA(5) : | 23.16 |
MA(20) : | 26.86 |
| MA(100) : | 29.72 |
MA(250) : | 28.48 |
|
| MACD | MACD : | -2.8 |
Signal : | -2.4 |
| %K %D | K(14,3) : | 4.6 |
D(3) : | 5.3 |
| RSI | RSI(14): 20.9 |
|||
| 52-week | High : | 49.5 | Low : | 16.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BEAM ] has closed above bottom band by 5.9%. Bollinger Bands are 6.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.57 - 22.76 | 22.76 - 22.88 |
| Low: | 20.48 - 20.67 | 20.67 - 20.8 |
| Close: | 21.34 - 21.65 | 21.65 - 21.85 |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Tue, 23 Apr 2024
Beam Therapeutics Stock: A 'Hold' Amid High Valuation And Volatile Revenue - Seeking Alpha
Tue, 23 Apr 2024
BMO maintains $57 target on Beam Therapeutics stock By Investing.com - Investing.com
Tue, 23 Apr 2024
Expert Ratings For Beam Therapeutics - Beam Therapeutics (NASDAQ:BEAM) - Benzinga
Sun, 07 Apr 2024
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S - Simply Wall St
Sat, 30 Mar 2024
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game? - Markets Insider
Thu, 28 Mar 2024
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 7.333e+007 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 13,110 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.5647e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -35.1 % |
| Operating Margin | 42 % |
| Return on Assets (ttm) | -7.9 % |
| Return on Equity (ttm) | -15.5 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 270.05 |
| Sales Per Share | 2.13395e+008 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -149 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 1.2 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 3.06 |
| Dividend | 0 |
| Forward Dividend | 1.345e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|